Vancocin Generics Launch As FDA Finds ViroPharma’s Label Fails “Significant New Use” Test
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA delivers an 87-page chef d'oeuvre that concludes the ViroPharma’s long-running battle to block ANDA approvals. In the citizen petition response, FDA rejects the firm’s scientific and legal arguments and concludes the antibiotic is not eligible for three years of Hatch-Waxman marketing exclusivity under a 2008 law. Although ViroPharma says it plans to sue FDA, the company may have bigger problems on its hands with an FTC investigation.
You may also be interested in...
FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions
46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.
FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions
46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.
Antibiotic Indications: Definition Of “Significant” Remains In FDA’s Hands After Vancocin Ruling
D.C. District Court Judge denies ViroPharma’s request for a preliminary injunction to require FDA to withdraw approval of three ANDAs, says company is unlikely to prevail in its suit challenging agency’s actions.